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EDITORIALCombination of Immunotherapy and
Radiotherapy—The Next Magic Step in the
Management of Lung Cancer?Lizza E. L. Hendriks, MD, PhD,a,* Jessica Menis, MD,b,c
Dirk K. M. De Ruysscher, MD, PhD,d Martin Reck, MD, PhDeKeywords: NSCLC; SCLC; Immune checkpoint inhibitors;
RadiotherapyImmune checkpoint inhibitors (ICIs), especially the anti–
programmed death ligand 1 (anti–PD-L1), have revolu-
tionized the treatment landscape of metastatic lung
cancer. Most patients with metastatic NSCLC without a
targetable driver mutation will receive first-line ICI,
either as monotherapy or in combination with chemo-
therapy.1 Atezolizumab (and in the near future, probably
durvalumab) in combination with chemotherapy has
become the first-line treatment for metastatic SCLC on
the basis of the IMpower133 and CASPIAN trials,
respectively.2,3 Furthermore, once the results of the
PACIFIC trial became known, adjuvant durvalumab
became the standard of care for patients with stage III
NSCLC that was not progressing after concurrent che-
moradiation (CCRT).4 Unfortunately, not all patients
obtain long-term benefit with these treatments, and new
treatment strategies are being explored to improve
overall survival (OS).
A logical option is to combine (thoracic) radiotherapy
with ICI because radiation up-regulates major histo-
compatibility complex class I antigens, increases tumor*Corresponding author.
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Journal of Thoracic Oncology Vol. 15 No. 2: 166-169antigen release, drives a polyclonal T-cell response, en-
hances CD8þ T-cell infiltration, limits T-cell exhaustion,
modulates the immune environment, provokes an
interferon gamma response, and can up-regulate PD-L1.5
The PACIFIC trial was the first randomized phase III
study to clinically validate these findings.4 Preclinically,
improvement in antitumor effects has been observed
when radiotherapy is given concurrently with or
immediately after anti–PD-L1, rather than sequentially.6
The PACIFIC trial results, which suggested that the OS
was better when durvalumab was given within 2 weeks
after the end of CCRT, are, therefore, consistent with
preclinical data.7 Therefore, concurrent radiotherapy-ICI
strategies are being tested in clinical trials. A possible
drawback of thoracic radiotherapy (TRT) combined with
ICI is the perceived increased risk of radiation pneu-
monitis. The two studies accompanying this editorial
shed some more light on the safety and efficacy of con-
current TRT and anti–PD-L1 in metastatic SCLC and
unresectable NSCLC, respectively.
Welsh et al.8 evaluated in a classic phase I 3 plus 3
design increasing doses of pembrolizumab (maximum
200mg) every 3 weeks combined with TRT (45 Gy per 15
daily fractions) administered sequentially after induction
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gated in the CREST study in patients with stage IV SCLC
after induction chemotherapy and prophylactic cranial
irradiation, showing no improvement in the primary end
point, 1-year OS.9 A dose of 45 Gy per 15 daily fractions is,
therefore, not a standard schedule in stage IV SCLC. No
dose-limiting toxicities were observed in the 33 patients
who received per-protocol treatment either within the
35-day dose-limiting toxicity window or in continued
follow-up. No grade 4 to grade 5 toxicity was observed,
but two patients experienced grade 3 toxicity (one rash,
one exacerbation of a preexisting unknown autoimmune
disorder) although the authors reported them as being
unrelated to treatment. The addition of TRT to pem-
brolizumab in this trial did not seem to increase immune-
related toxicity because grade 3 to grade 5 immune-
related toxicity was also around 10% in monotherapy
anti–PD-L1 SCLC trials.10 Objective response rate does
not seem to improve with the addition of TRT, as the
objective response rate was 12% in a single-arm phase II
pembrolizumab maintenance trial11 compared with 15%
(measured by Immune-Related Response Criteria) in the
current trial. More importantly, at a median follow-up of
7.3 months, the median progression-free survival (PFS)
and OS were 6.1 (95% confidence interval: 4.1–8.0) and
8.4 months (95% confidence interval: 6.7–10.1), and 6-
month PFS and OS rates were 50.3% and 76.5%,
respectively. Although these results are similar to those
of the CREST trial,9 in the latter, patients were random-
ized after having achieved a remission after induction
chemotherapy. In IMpower133, survival was higher, with
a median OS of 12.3 months (atezolizumab) versus 10.3
months (placebo).3
The second study is the phase II DETERRED study
from Lin et al.,12 in which atezolizumab with CCRT was
evaluated in unresectable NSCLC (15% stage IIB, others
stage III). Patients had to be adequately staged with brain
magnetic resonance imaging and 18F-deoxyglucose-posi-
tron emission tomography-computed tomography scan
and be eligible for CCRT. As a safety run-in, part 1 con-
sisted of treatment with intensity-modulated radiation
therapy (protons versus photons, 60–66 Gy in 30–33
daily fractions) concurrent with once-weekly carboplatin
area under the curve 2.0 and paclitaxel 50 mg/m2, fol-
lowed by two cycles of consolidation carboplatin area
under the curve 6.0, paclitaxel 200 mg/m2 and 1200 mg
atezolizumab, followed by maintenance atezolizumab
every 3 weeks for up to 1 year. Part 2 consisted of the
same schedule, but atezolizumab was already introduced
concurrently with the CCRT. The primary end points
were safety and/or tolerability. Ten of the 15 patients
in part 1 were treated with consolidation atezolizumab,
and 30 of 37 patients in part 2 were treated with atezo-
lizumab and CCRT. In both parts, 80% of the patientsexperienced at least one episode of grade 3þ adverse
events, which is slightly higher than that in CCRT without
ICI13 but is comparable with the phase II NICOLAS trial
that assessed nivolumab given concomitantly with
CCRT.14 In the DETERRED study, 20% to 30% had grade
3þ immune-related toxicity, much higher than what was
reported in the PACIFIC trial (3.4%).15 However, the
percentage of grade 3þ dyspnea per (radiation) pneu-
monitis was low (10% in part 1 and 3% in part 2), and
comparable with the grade 3þ pulmonary adverse events
in chemoradiation without ICI13 and the PACIFIC (3.4%
pneumonitis, 1.5% dyspnea) and NICOLAS trials (10%
pneumonitis).14,15 All immune-related toxicities were
reversible with steroids and supportive care. Two pa-
tients in part 2 developed a recurrence before the start of
consolidation therapy: one had a Kirsten Rat Sarcoma
Viral oncogene homolog (KRAS)/serine/threonine kinase
11 (STK11). co-mutation, and the other had an anaplastic
lymphoma kinase (ALK) rearrangement. With a median
follow-up of 22.5 months (part 1) and 15.3 months (part
2), median PFS was 12.5 and 13.2 months, respectively,
and median OS was 22.8 months and not reached (NR),
respectively. PD-L1 status (evaluable in 34 of 40 patients)
was not associated with recurrence. These survival data
are similar to those of CCRT regimens without ICI, such as
the PROCLAIM study.13 Although difficult to compare
with the PACIFIC trial4 (survival measured from
randomization after CCRT till death, instead from start of
CCRT), the concurrent ICI-CCRT regimen does not strik-
ingly improve survival.What Can We Learn From These Trials,
and How Should We Proceed?
Both studies report that the combination of TRT and
anti–PD-L1 is feasible. In contrast, survival in both trials
does not seem to improve with the combination,
compared with historical data. Better patient selection
and biomarker research are needed, and these should be
evaluated in well-designed randomized trials. Further-
more, for both studies, dose volume histogram con-
straints were not given, making the interpretation of
radiotherapy toxicity difficult.
In metastatic SCLC, monotherapy ICI trials have re-
ported disappointing results, with the suggestion that
patients with a high PD-L1 expression or a high tumor
mutational burden could benefit most. However, this has
not been evaluated prospectively in a randomized trial.10
Both the IMpower133 and the CASPIAN trials reported
that the addition of ICI to platinum-doublet chemo-
therapy improved survival, although modestly.2,3 In both
trials, survival curves separated late, and patients who
would benefit could not be identified.2,3 It is possible
that the addition of TRT to a chemo-ICI regimen can
168 Hendriks et al Journal of Thoracic Oncology Vol. 15 No. 2make SCLC more immunogenic, but the optimal treat-
ment sequence, radiation dose, and fractionation scheme
should be evaluated prospectively. Many trials are
ongoing (e.g., NCT02402920 and NCT02934503).
Moreover, combinations of anti-CTLA4, anti-PD1, and
TRT after completion of chemotherapy are also being
evaluated (e.g., NCT03043599 and NCT0392370), of
which the STIMULI trial (NCT02046733) has completed
recruitment. A next step could be the addition of other
immune-modulating drugs such as poly (ADP-ribose)
polymerase (PARP)-inhibitors, as preclinically, PARP-
inhibitors are radiosensitizers and immune modula-
tors.16,17 NCT03532880 is currently evaluating the
safety of olaparib, a PARP-inhibitor, combined with
radiotherapy; NCT03923270 is evaluating the safety of
TRT followed by durvalumab with or without trem-
elimumab or olaparib.
In unresectable NSCLC, adjuvant durvalumab after
CCRT has become the standard, but reliable patient-
related factors or biomarkers to identify those who
benefit most do not exist.4 Only PD-L1 less than 1% was
associated with the lack of OS benefit, but this was
evaluated in an unplanned post hoc analysis requested
by the European Medicines Agency (EMA). Molecular
analysis in unresectable NSCLC would be of interest
because in metastatic NSCLC, those with non–smoking-
associated driver alterations such as EGFR and ALK, or
those with STK11 or kelch like ECH associated protein 1
(KEAP1) mutations often obtain very limited benefit
from ICIs,18 as was also seen in two patients in the
DETERRED trial. Furthermore, patients with a driver
alteration who are treated with a tyrosine kinase inhib-
itor after ICI seem to be at an increased risk of tyrosine
kinase inhibitor–associated toxicity.19 Finally, in the
DETERRED trial, 22% of patients were treated with
protons instead of photons, but differences in immune
activation are not clear yet. NCT01993810 is evaluating
protons versus photons in this setting.
Moreover, detection of progressive disease becomes a
challenge in patients treated with CCRT and ICI, as both
radiation and ICI can cause pneumonitis, which is
sometimes difficult to distinguish from progressive dis-
ease. Alternative follow-up methods such as longitudinal
circulating tumor DNA (ctDNA) or electronic nose
(ENOSE) measurements would be of interest, as both
ctDNA and ENOSE patterns are associated with outcome
in ICI-treated metastatic NSCLC.20,21
Finally, long-term toxicities are not known yet. It is
possible that patients treated with TRT-ICI will develop
late pulmonary fibrosis or cardiac toxicity. The latter is
interesting as PD-L1 is expressed on cardiomyocytes, and
preclinically, excess cardiac mortality was found in mice
treated with cardiac irradiation and an anti–PD-1.22Different new strategies are currently being tested
in unresectable NSCLC. Examples are neoadjuvant
ICI followed by chemoradiation (e.g., NCT04085250);
other immune agents added to chemoradiation (e.g.,
M7824 [NCT03840902], oleclumab or monalizumab
[NCT03822351]); anti-CTLA4 added to chemoradiation
plus anti–PD-1 (e.g., CheckMate73L [NCT04026412], or
NCT03663166); and the addition of stereotactic body
radiation to chemoradiation and durvalumab (e.g.,
NCT03589547). Toxicity and long-term outcomes are
awaited.
In the end, ultimate success will be defined by the
possibility of selecting those patients who are likely to
have long-term survival in combination with a main-
tained or improved quality of life. More insight into the
biological mechanisms underlying treatment resistance
and toxicity is needed to improve the outcome for other
patients. Biomarkers should be an integral part of any
study, and prolonged detailed follow-up is needed.
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